Alpha 1-Antitrypsin is a protein found in your blood. Its main job is to protect your lungs and liver from damage caused by certain enzymes. These enzymes are normally involved in breaking down old cells, but if they get out of control, they can harm healthy tissues. Alpha 1-Antitrypsin acts like a shield to stop these enzymes.
Every report comes from a Lived member, sent anonymously.
Have you tried alpha 1-Antitrypsin for Alpha-1 Antitrypsin Deficiency?
Alpha-1 antitrypsin (AAT) is a protective protein that the liver normally makes and releases into the blood. As a medicine, it is purified from donated human plasma and given by infusion to adults who have emphysema caused by severe alpha-1 antitrypsin deficiency (AATD), an inherited condition in which the body makes too little working AAT. This treatment is called augmentation therapy because it adds back the missing protein. In the US it is sold as Prolastin-C Liquid, Zemaira, Glassia and Aralast NP, which are made by different companies but are used in the same way. It is meant only for people whose severe deficiency has been confirmed by a blood level and genetic testing, and who already have lung damage. It is not a treatment for ordinary COPD (chronic obstructive pulmonary disease) or for people who carry only one altered copy of the gene. It also does not treat the liver disease that AATD can cause, because that damage comes from abnormal AAT building up inside liver cells rather than from a shortage of it in the blood.
In the lungs, white blood cells release an enzyme called neutrophil elastase to fight infection and clear irritants. AAT normally keeps this enzyme in check. When AAT is very low, elastase goes on to break down the elastic walls of the air sacs, which over years produces emphysema, especially in people who smoke. Weekly infusions raise the AAT level in the blood and in the fluid lining the lungs, restoring some of that protection. The level climbs over the first few weeks and is then kept up by regular doses, since the protein is slowly used up over several days. Infusions raise AAT levels but do not bring them fully to normal, and they cannot repair air sacs that are already damaged. The aim is to slow further loss.
AAT is given into a vein (intravenously), usually once a week, with the dose based on body weight. It is not a pill. Depending on the product, it comes as a ready-to-use liquid or as a powder mixed with sterile water just before use, and at the usual rates a dose often takes around 15 minutes, longer if the infusion is slowed for comfort. Infusions may be given at a clinic or infusion center, by a home-infusion nurse, or, for some products such as Glassia, by a trained patient or caregiver at home. Treatment is ongoing, so keeping to the weekly schedule matters for keeping levels up. People who infuse at home are usually asked to keep a log of each dose, including the lot number and any reactions. The brands are not interchangeable without the prescriber's direction, because preparation and infusion rates differ.
Most people tolerate infusions well. Headache, dizziness, tiredness, nausea or diarrhea, cold-like symptoms such as a runny nose or sore throat, and bruising where the needle goes in are among the more commonly reported effects. Some people feel lightheaded afterward, and resting for a short while after the infusion can help. Allergic reactions are uncommon but can be serious. Itching, hives or flushing during an infusion is a reason to stop or slow it and contact the care team right away. Swelling of the lips, tongue or throat, wheezing, trouble breathing, chest tightness or fainting can signal anaphylaxis: stop the infusion, use epinephrine if it has been prescribed for home infusions, and call 911.
AAT is not known to have important interactions with other medicines. The main person to avoid it is someone with IgA deficiency (a low level of the antibody immunoglobulin A) who has developed antibodies against IgA, because the products can contain traces of IgA and may trigger a severe allergic reaction. It is also not used after a previous anaphylactic reaction to AAT. Because it is made from human plasma, there is a small remaining risk of passing on an infection, even though donors are screened and the manufacturing process removes or inactivates known viruses. Smoking undermines the treatment: smoke speeds up lung damage in AATD and is likely to make augmentation less effective, so guidelines generally do not offer it to people who are still smoking. Stopping smoking is the single most important step for anyone with AATD.
Augmentation therapy is a long-term treatment, continued week after week for as long as it is judged worthwhile. It is not meant to ease breathlessness quickly; its aim is to slow lung damage over years, so breathing may not feel any different. Inhalers, pulmonary rehabilitation, vaccinations and other usual COPD care continue alongside it. The evidence for clinical benefit is mixed. In clinical trials, people receiving infusions lost lung density on computed tomography (CT) scans somewhat more slowly than those on placebo, which suggests slower emphysema, but trials have not shown fewer flare-ups (exacerbations), better quality of life, better breathing tests or longer survival. Guidelines in different countries range from recommending it for people who meet strict criteria to suggesting it be considered case by case, and its high cost and weekly routine are real factors in the decision. Follow-up usually includes yearly breathing tests and regular checks of liver health, since AATD can affect the liver as well.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking alpha 1-Antitrypsin, what you've noticed, or ask the community a question.